Pfizer's pneumonia vaccine hits goals in post-approval trial

02/25/2014 | Reuters · Bloomberg Businessweek

Pfizer said its pneumonia vaccine Prevnar 13 met both the main and secondary goals of a post-approval 85,000-patient trial, one of the largest drug studies ever conducted. Data showed that the vaccine prevented a first episode of community-acquired pneumonia and a first episode of invasive bloodstream infections in people 65 and older. The trial's success could boost the vaccine's sales by $1 billion or more, analysts said.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA